The pharmaceutical industry is quickly evolving; to stay relevant and competitive, companies need to stay on top of the most recent trends and technologies.
The UK health service has well over a decade’s experience of dealing with biosimilars, but the NHS acknowledges that it has yet to make the most of these drugs.
A move towards integrated care systems (ICS), complete with new primary care roles, and a greater focus on public health is shaking the healthcare system to its core.
NICE provides a downloadable excel file of details of Technology Appraisal (TAs) recommendations which can help explore trends in deals that play a role in NICE recommendations made.
